Powered by

Assembly flop sees it pivot from curative to chronic hep B focus

Nov 06, 2020 - FierceBiotech

Assembly Bio was hoping its experimental hepatitis B drug could be a functioning cure for the viral liver disease, but a midstage flop has seen the biotech rethink this path in the near term.

The Californian biotech had been running an open-label phase 2 test for vebicorvir (VBR) in chronic hep B patients alongside a nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI).

The idea was that you could treat patients with this combo for 12 to 18 months, take them off therapy and...